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EVOLUTION OF THE PHARMACY PRACTICE MODEL TO IMPROVE PA-
TIENT AND LEARNER OUTCOMES: A PARTNERSHIP IN PATIENT CARE
INITIATIVE (PIPC) IN THE HSCT POPULATION
Khan, T.1, Muluneh, B.1, Alexander, M.1, Lasater, K.2, Hoang, V.2,
Olson, L.1, Patel, R.1, Mark, N.1, Smith, K.1, Savage, S.1, Poppe, L.1
1UNCHospitals, Chapel Hill, NC; 2University of North Carolina, Chapel
Hill, NC
Recent studies by the American Society of Bone Marrow Trans-
plantation (ASBMT) have projected an increase in the number of he-
matopoietic stem cell transplants (HSCT)in the coming years, which
will grow the need for clinical pharmacists specialized in caring for
HSCT patients. However, major deterrents to meeting this in-
creased demand of HSCT Clinical Pharmacists are the low capacity
of residency training programs and exposure to HSCT as a student
or resident learner.
The Partnership in Patient Care (PIPC) initiative is a joint ef-
fort between the UNC Eshelman School of Pharmacy and the
UNC Hospitals’ Department of Pharmacy, with a goal to improve
patient care by expanding patient care services of the pharmacy
team, while improving the overall experience and capacity for
learners. The HSCT acute care service, as part of the PIPC initia-
tive, conducted a pilot program to evaluate the feasibility of in-
creasing learner capacity while expanding pharmacy services.
The pilot represented a paradigm shift from a model where the
clinical specialist (CS) was the major driver of outcomes to the
CS evolving into an Attending Pharmacist (AP) and managing
a pharmacy team to drive the direct patient care outcomes. A lay-
ered learning practice model (LLPM) was created where the AP
oversees Decentral Pharmacists (DP), a resident, and a student.
Improvements during the LLPM included 100% capture rate of
new admission medication histories, completion of all patients’
pre-discharge insurance benefits investigation, accomplishing
100% compliance for the National Patient Safety Goals of medi-
cation reconciliation and discharge counseling, and formal docu-
mentation of pharmacy activities in the patient’s electronic
medical record (Table 1). Mobilizing learners through the
LLPM allowed them more time spent directly with the patient
to create a stronger pharmacist-patient relationship. The ability
of the AP to delegate responsibilities for pharmacy activities in-
creased educational opportunities and increased the sense of own-
ership to offer a wider range of pharmacy services to the patient
and for the medical team. While challenges exist and the model re-Table. Correlation of Quality of Life and Medication Burden
QoL Domain
Total number of
scheduled pills per day
p (p)
Maximum poss
per day (schedul
r r
Pre-HSCT Pre-HSCT (N 5 43)
Physical well being -0.22 0.15 (0.41) -0.44
Social well being -0.37 0.02 (0.01) -0.26
Emotional well being -0.06 0.69 (0.91) 0.16
Functional well being -0.16 0.3 (0.55) -0.39
Overall QoL -0.25 0.11 (0.27) -0.43
1 Year Post-HSCT Pre-HSCT (N 5 41)
Physical well being -0.05 0.75 (0.81) -0.47
Social well being 0.12 0.44 (0.94) -0.03
Emotional well being 0.08 0.64 (0.62) -0.30
Functional well being 0.14 0.37 (0.35) -0.23
Overall QoL 0.08 0.61 (0.54) -0.38
1 Year Post-HSCT 1 Year Post-HSCT (N 5 41)
Physical well being -0.17 0.30 (0.61) -0.60
Social well being -0.21 0.18 (0.17) -0.20
Emotional well being 0.22 0.17 (0.11) -0.12
Functional well being -0.09 0.58 (0.99) -0.36
Overall QoL -0.10 0.54 (0.93) -0.47
r 5 Pearson correlation coefficient (p) 5 adjusted for age, gender, ECOG pe
S240quires further improvements to create sustainability, the patient
benefits gained during these pilots are significant enough to pursue
continuation of this model in the HSCT setting.
Table 1. PIPC Initiative Accomplishment
Non LLPM LLPMible doses
ed and prn)
p (p)
Maximum possib
day (scheduled
r
0.003 (0.01) -0.40
0.09 (0.05) -0.32
0.30 (0.35) -0.18
0.01 (0.04) -0.31
0.003 (0.01) -0.40
0.002 (0.002) -0.45
0.83 (0.29) -0.13
0.06 (0.07) -0.30
0.14 (0.07) -0.24
0.02 (0.006) -0.39
<0.0001 (0.0004) -0.68
0.22 (0.13) -0.24
0.47 (0.55) -0.20
0.02 (0.06) -0.43
0.002 (0.007) -0.57
rformance statusMonthsle pills per
and prn)
p (
0.008 (
0.04
0.24
0.04 (
0.008 (
0.003 (
0.42 (
0.06 (
0.13 (
0.01 (
<0.0001 (
0.13 (
0.22 (
0.005 (
0.0001 (MonthsTangible Benefits (100% Capture
Rate)Admission History Review x x
Admission Interview By Students x
Admission Chemotherapy Counseling x
Admission Medication Reconciliation x x
Discharge Medication Review x x
Discharge Counseling by Student/
Resident
xDischarge Insurance Benefits
InvestigationxDischarge Rx Facilitation x x
Discharge Summaries x
Intangible Benefits
Increased DP involvement x
Increased Pharmacy FSR Involvement x
Increase Awareness of Pharmacy
Services/Functions
xIncreased Resident Awareness of
Practical CS DutiesxIncreased Pharmacy Visibility and
ResponsibilityxCS indicates Clinical Specialist; DP, Decentral Pharmacist; FSR, Financial
Services Representative.
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Background: Literature suggests medication burden is related to
patient satisfaction; this relationship has not been examined in allo-
geneic hematopoietic stem cell transplant (aHSCT) patients. Wep)
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Oral Presentations S241previously reported aHSCT patients take a median of 17 (range 3-
49) medications daily at Mayo Clinic. This study aimed to determine
if medication burden correlates with quality of life (QoL) at 1 year
following HSCT.
Methods: As part of an ongoing, IRB approved QoL study we ex-
amined the cross-sectional relationship between medication burden
and QoL among all adult aHSCT patients with adequate documen-
tation and follow-up between 7/1/09 and 9/30/10. Medication bur-
den was assessed by number of scheduled medications, maximum
possible doses and maximum possible pills per day reconciled by
a pharmacist pre-HSCT and 1 year post-HSCT. QoL was assessed
by the Functional Assessment of Cancer Therapy (FACT)-General
(version 4) during pre-HSCT evaluation and FACT-BMT 1 year
post-HSCT.
Results: During the study period, 57 patients received an aHSCT
and enrolled in the QoL study; 43 patients were included. Patients
were excluded for death before 1 year (n 5 13), incomplete medi-
cation record (n 5 1), missing post-HSCT QoL data (n 5 2). Me-
dian patient age was 55 years (range of 24-71); 50% of patients
were male and most patients had an ECOG performance score of
0 or 1 (n 5 1 ECOG of 2). Pre-HSCT total scheduled pills per
day negatively correlated with social well being. Pre-HSCT,
a higher number of maximum possible pills per day (scheduled
and prn) was associated with worse pre-transplant QoL across do-
mains of physical, social, functional, and overall well-being. The as-
sociations with physical, social, and total well-being remained
significant after adjustment for age, gender, and ECOG perfor-
mance score. A higher pre-HSCT maximum possible pills per
day correlates with worse physical and overall well being 1-year
post-HSCT. Post-transplant a higher number of maximum possi-
ble pills per day negatively correlated with physical, functional,
and overall well-being 1 year post-transplant, even after covariate
adjustment.
Conclusion: These data offer preliminary evidence that maximum
daily pill count (scheduled and prn) might be a significant predictor
of QoL among HSCT recipients. Better understanding of which as-
pects of medication burden (e.g., pill count, medication type) affect
domains of QoLmay help identify possible medication management
strategies to improve QoL.102
EFFECT OF CYTOXAN DOSING ON HEMATOPOIETIC STEM CELL (HSC)
MOBILIZATION EFFICACY, TOXICITY, AND COST IN SUCCESSIVE CO-
HORTS OF NON-HODGKIN’S LYMPHOMA (NHL) PATIENTS
Sanacore, M.F.1, Sizemore, C.A.1, Xhang, X.2, Schipani, B.1,
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Background:Cyclophosphamide (Cy) has been shown to be an ef-
fective regimen for HSC mobilization in NHL patients undergoingTable.
Cy2 (n 5 28) Cy3 (n 5 31) Cy4 (n 5 28
Collect $2x106 in #2 days 39% 87% 82%
Collect$5x106 in #2 days 14% 42% 46%
Collect$5x106 in all days 18% 45% 64%
Collect$2x106 in all days 89% 100% 100%
Median # of collections 3 2 2
% Patients hospitalized for FN 0% 16% 32%
Hospitalization Days (median) 0 3 4
Days of G-CSF (median) 11.5 12.5 10.5
% Pts receiving plerixafor 32% 42% 4%
Relative Mobilization Cost
(normalized to Cy4)
1.47 1.37 1.00autologous stem cell transplantation (ASCT). However, the opti-
mal dose to be used, which maximizes HSC collection yields while
minimizing febrile neutropenia and other toxicities, remains con-
troversial. Three successive cohorts of NHL patients who received
G-CSF and Cy at doses of either 4g/m2 (Cy4), 2g/m2 (Cy2) or 3g/
m2 (Cy3) were compared.
Methods: 31 pts undergoing Cy3 mobilization between October
2009 and August 2011 were retrospectively analyzed and com-
pared to our historical Cy2 (n 5 28) and Cy4 (n 5 28) data.
Minimal and optimal yield was defined as collection of $2 x
106 and $5 x 106 CD34+ cells/kg, respectively. Apheresis was
initiated utilizing WBC and CD34+ cell count to guide start of
collection and preemptive plerixafor use, whereas in historical
Cy4 and Cy2 cohorts, plerixafor was only used following mobi-
lization failure.
Results:Minimal cell dose required for ASCT was achieved in the
majority of patients in all groups (89%, 100% and 100% of Cy2, 3,
and 4 pts, respectively). However, the collection efficiency clearly
favored Cy3 and Cy4, with the proportion of patients collecting
$2 x 106 CD34+ cells/kg in 2 days being 87% and 82%, respec-
tively vs. 39% for Cy2 (p\0.001). In contrast, toxicity, as measured
by % febrile neutropenia and median hospitalization days, favored
Cy2 (0%, 0d) compared with Cy4 (32%, 4d, p 5 0.002), with Cy3
falling intermediate between these groups (16%, 3d). Requirement
for Plerixafor was significantly higher for both Cy2 (32%) and Cy3
(42%), compared with Cy4 (4%, p 5 0.003). Relative cost clearly
favored Cy4, when accounting for the combined costs of Cy, G-
CSF, plerixafor, hospitalization, and apheresis, with Cy3 and Cy2
costing approximately 37% and 47% more, respectively, per pa-
tient mobilization.
Conclusions: Although Cy2, 3, and 4 are all effective mobilizing
regimens, collection efficiency, toxicity, and cost vary greatly. Both
Cy3 and Cy4 improve collection efficiency, at the expense of in-
creased hospitalization, particularly with Cy4. Cy4 appears to max-
imize collection efficiency while minimizing plerixafor use and
overall cost. Further improvements in supportive care strategies to
reduce the incidence of febrile neutropenia and associated hospital-
ization are clearly needed.103
ONCE DAILY DOSE (ODD) LORAZEPAM (LO) FOR SEIZURE PROPHYLAXIS
IN CONJUNCTIONWITH ONCE DAILY DOSE BUSULFAN (BU) FOR PEDIAT-
RIC PATIENTS UNDERGOING REDUCED INTENSITY CONDITIONING (RIC)
FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HSCT)
Shinkle, M.1, Powers, K.1, Tobin, M.1, Kletzel, M.1,2 1Children’s Memo-
rial Hospital, Chicago, IL; 2Northwestern University Feinberg School of
Medicine, Chicago, IL
BU is an alkylating agent used as part of conditioning for
HSCT. It is known to cause seizures in the 3rd and 4th day of) P-value
Pairwise Comparison (significant if p-value<0.017
based on Bonferroni adjustment)
Cy2 vs Cy3 Cy2 vs Cy4 Cy3 vs Cy4
<0.001 <0.001 0.001 0.597
0.022 0.019 0.009 0.729
0.002 0.025 <0.001 0.141
n.s N/A N/A N/A
<0.001 <0.001 0.011 0.830
0.002 0.062 0.002 0.127
0.004 0.033 0.002 0.113
n.s N/A N/A N/A
0.003 0.437 0.005 <0.001
